BURNABY, BC, Sept. 25 /CNW/ - Twinstrand Therapeutics Inc. today
announced that it has filed an Investigational New Drug (IND) Application with
the U.S. Food and Drug Administration (FDA) for the immunization of humans
with a benign ricin-like toxoid.
"This is the first significant step in the clinical development of an
antidote to ricin poisoning," says Twinstrand's CEO Dr. Thor Borgford. Ricin,
a highly potent toxin derived from the castor bean plant, is a significant
bioterror threat for which there is currently no antidote.
In September 2006, Twinstrand announced a contract with the U.S.
Department of Defense's Defense Threat Reduction Agency (DTRA) to fund
development of a medical countermeasure to ricin. Twinstrand anticipates that
an antidote product will be available for emergency use in humans by the end
of 2008, says Dr. Borgford.
About Twinstrand - Twinstrand is a private clinical-stage
biopharmaceutical company dedicated to the discovery and development of
biological drugs for the treatment of life threatening diseases. Established
in 1995, the company has offices and laboratories in Burnaby, British
Twinstrand's platform is based on a unique 'prodrug' targeting concept
that is able to descriminate between healthy and diseased cells by the
differential expression of certain proteases in these tissues. Research is
currently focused on the development of drugs for the treatment of cancer. In
addition, the Company has ownership of a platform with broad potential in the
treatment of diseases including, but not limited to; hepatitis C, HIV/AIDS,
hepatitis A, cytomegalovirus, parasitic infections such as malaria and
schistosomiasis, and fungal diseases.
For further information:
For further information: visit our website at www.twinstrand.com or
contact Marjorie Co at email@example.com or at (604) 415-7180